Assessment of Long-term Cardiovascular Health and Exercise Capacity in Athletes Post-COVID-19: Findings from the COSMO Study - Scorecard - MDSpire

Assessment of Long-term Cardiovascular Health and Exercise Capacity in Athletes Post-COVID-19: Findings from the COSMO Study

  • By

  • Jana Schellenberg

  • Lynn Matits

  • Johannes Kersten

  • Daniel A. Bizjak

  • Florian Horn

  • Johannes Hell

  • Sebastian Viktor Waldemar Schulz

  • Eric Schwarz

  • Johannes Kirsten

  • April 29, 2026

  • 0 min

Share

Clinical Scorecard: Assessment of Long-term Cardiovascular Health and Exercise Capacity in Athletes Post-COVID-19: Findings from the COSMO Study

At a Glance

CategoryDetail
ConditionMild SARS-CoV-2 infection in athletes
Key MechanismsEvaluation of cardiac structure, myocardial deformation, and cardiopulmonary performance over 12 months post-infection
Target PopulationElite and recreational athletes aged ≥18 years recovering from mild COVID-19
Care SettingSports medicine and rehabilitation outpatient clinical follow-up

Key Highlights

  • No evidence of impaired myocardial structure, strain, or cardiopulmonary performance at 12 months post mild COVID-19 infection.
  • Baseline aerobic fitness (VO2peak) strongly predicts cardiopulmonary performance at 12-month follow-up.
  • Minor physiological changes observed in diastolic indices and body composition without adverse remodeling.

Guideline-Based Recommendations

Diagnosis

  • Use echocardiography including strain imaging (LV/RV GLS) to assess myocardial function post-COVID-19 in athletes.
  • Perform cardiopulmonary exercise testing (CPET) to evaluate exercise capacity and ventilatory parameters.

Management

  • Support return to sport in asymptomatic athletes after mild COVID-19 based on stable cardiac and exercise performance findings.
  • Monitor athletes longitudinally with clinical and functional assessments to detect any late cardiac changes.

Monitoring & Follow-up

  • Repeat echocardiographic and CPET evaluations at baseline (~3 months post-infection) and 12 months to assess stability.
  • Track body composition and diastolic function indices as part of comprehensive follow-up.

Risks

  • Clinically significant myocardial involvement (e.g., myocarditis) is rare (~1%-3%) in athletes with mild COVID-19.
  • No evidence of adverse cardiac remodeling or impaired cardiopulmonary function at 12 months in this population.

Patient & Prescribing Data

Adult elite and recreational athletes with mild SARS-CoV-2 infection

Return to sport is safe in asymptomatic athletes with preserved myocardial and cardiopulmonary function at 12 months; baseline fitness is a key predictor of long-term exercise capacity.

Clinical Best Practices

  • Incorporate advanced echocardiographic strain imaging for sensitive detection of subclinical myocardial changes post-COVID-19.
  • Use CPET to objectively measure cardiopulmonary performance and guide return-to-play decisions.
  • Consider baseline aerobic fitness as a prognostic factor for long-term recovery in athletes.
  • Maintain regular follow-up assessments to ensure stable cardiac function and exercise capacity.

References

Original Source(s)

Related Content